Biblio
. .
c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clin Transl Med. 2023;13(8):e1364.
. Efficacy of daratumumab in newly diagnosed multiple myeloma patients with 1q21 gain. Int J Hematol. 2024.
.